{  
   "types" : {
      "Bookmark" : {
         "pluralLabel" : "Bookmarks"
      },
      "Publication" : {
         "pluralLabel" : "Publications"
      },
      "GoldStandardPublication" : {
         "pluralLabel" : "GoldStandardPublications"
      },
      "GoldStandardBookmark" : {
         "pluralLabel" : "GoldStandardBookmarks"
      },
      "Tag" : {
         "pluralLabel" : "Tags"
      },
      "User" : {
         "pluralLabel" : "Users"
      },
      "Group" : {
         "pluralLabel" : "Groups"
      },
      "Sphere" : {
         "pluralLabel" : "Spheres"
      }
   },
   
   "properties" : {
      "count" : {
         "valueType" : "number"
      },
      "date" : {
         "valueType" : "date"
      },
      "changeDate" : {
         "valueType" : "date"
      },
      "url" : {
         "valueType" : "url"
      },
      "id" : {
         "valueType" : "url"
      },
      "tags" : {
         "valueType" : "item"
      },
      "user" : {
         "valueType" : "item"
      }      
   },
   
   "items" : [
   	  
      {
         "type" : "Publication",
         "id"   : "https://puma.ub.uni-stuttgart.de/bibtex/26b61855e68cc3c6dffa5f6b331087421/slegewie",         
         "tags" : [
            "Alternative","Antigens,","CD19,","Cell","Epitopes,","Heterogeneous-Nuclear","Humans,","Isoforms,","Leukemia-Lymphoma,","Local,","Lymphoblastic","Mutagenesis,","Mutation,","Neoplasm","Polypyrimidine","Precursor","Protein","Protein,","Proteins","RNA","RNA-Binding","Recurrence,","Ribonucleoproteins,","Sites,","Splice","Splicing,","Tract-Binding"
         ],
         
         "intraHash" : "6b61855e68cc3c6dffa5f6b331087421",
         "interHash" : "e5f13d1833dc05db51f0b0e500c850c1",
         "label" : "High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling CD19 splicing and CART-19 therapy resistance",
         "user" : "slegewie",
         "description" : "",
         "date" : "2025-03-05 15:52:38",
         "changeDate" : "2025-03-05 15:52:38",
         "count" : 2,
         "pub-type": "article",
         "journal": "Nature Communications",
         "year": "2022", 
         "url": "", 
         
         "author": [ 
            "Mariela Cortés-López","Laura Schulz","Mihaela Enculescu","Claudia Paret","Bea Spiekermann","Mathieu Quesnel-Vallières","Manuel Torres-Diz","Sebastian Unic","Anke Busch","Anna Orekhova","Monika Kuban","Mikhail Mesitov","Miriam M. Mulorz","Rawan Shraim","Fridolin Kielisch","Jörg Faber","Yoseph Barash","Andrei Thomas-Tikhonenko","Kathi Zarnack","Stefan Legewie","Julian König"
         ],
         "authors": [
         	
            	{"first" : "Mariela",	"last" : "Cortés-López"},
            	{"first" : "Laura",	"last" : "Schulz"},
            	{"first" : "Mihaela",	"last" : "Enculescu"},
            	{"first" : "Claudia",	"last" : "Paret"},
            	{"first" : "Bea",	"last" : "Spiekermann"},
            	{"first" : "Mathieu",	"last" : "Quesnel-Vallières"},
            	{"first" : "Manuel",	"last" : "Torres-Diz"},
            	{"first" : "Sebastian",	"last" : "Unic"},
            	{"first" : "Anke",	"last" : "Busch"},
            	{"first" : "Anna",	"last" : "Orekhova"},
            	{"first" : "Monika",	"last" : "Kuban"},
            	{"first" : "Mikhail",	"last" : "Mesitov"},
            	{"first" : "Miriam M.",	"last" : "Mulorz"},
            	{"first" : "Rawan",	"last" : "Shraim"},
            	{"first" : "Fridolin",	"last" : "Kielisch"},
            	{"first" : "Jörg",	"last" : "Faber"},
            	{"first" : "Yoseph",	"last" : "Barash"},
            	{"first" : "Andrei",	"last" : "Thomas-Tikhonenko"},
            	{"first" : "Kathi",	"last" : "Zarnack"},
            	{"first" : "Stefan",	"last" : "Legewie"},
            	{"first" : "Julian",	"last" : "König"}
         ],
         "volume": "13","number": "1","pages": "5570","abstract": "Following CART-19 immunotherapy for B-cell acute lymphoblastic leukaemia (B-ALL), many patients relapse due to loss of the cognate CD19 epitope. Since epitope loss can be caused by aberrant CD19 exon 2 processing, we herein investigate the regulatory code that controls CD19 splicing. We combine high-throughput mutagenesis with mathematical modelling to quantitatively disentangle the effects of all mutations in the region comprising CD19 exons 1-3. Thereupon, we identify ˜200 single point mutations that alter CD19 splicing and thus could predispose B-ALL patients to developing CART-19 resistance. Furthermore, we report almost 100 previously unknown splice isoforms that emerge from cryptic splice sites and likely encode non-functional CD19 proteins. We further identify cis-regulatory elements and trans-acting RNA-binding proteins that control CD19 splicing (e.g., PTBP1 and SF3B4) and validate that loss of these factors leads to pervasive CD19 mis-splicing. Our dataset represents a comprehensive resource for identifying predictive biomarkers for CART-19 therapy.",
         "language" : "eng",
         
         "pmid" : "36138008",
         
         "file" : "Volltext:C\\:\\\\Users\\\\SL\\\\Zotero\\\\storage\\\\CJS52XEJ\\\\Cortés-López et al. - 2022 - High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling CD19 splicing.pdf:application/pdf",
         
         "issn" : "2041-1723",
         
         "pmcid" : "PMC9500061",
         
         "doi" : "10.1038/s41467-022-31818-y",
         
         "bibtexKey": "cortes-lopez_high-throughput_2022"

      }
	  
   ]
}